-
If youre not in full compliance with the National Safety Patient Goals for 2004 from the Oakbrook Terrace, IL-based Joint Commission on Accreditation of Healthcare Organizations, you have a lot to worry about.
-
-
A Canadian physician has developed a device that could replace drug-eluting stents in preventing restenosis or re-narrowing of coronary arteries and help to heal diseased arteries. The first implantation of an antibody-coated stent on a human was performed in May at the Thoraxcentre of the University Hospital Rotterdam (Rotterdam, the Netherlands).
-
In a webcast conference call last month, replacement heart manufacturer Abiomed (Danvers, Massachusetts) provided a sketchy overview of its current activities, with that overview tending to underline at least two critical points for the company:
-
AmeriNet (St. Louis, Missouri), a healthcare group purchasing organization, has renewed its immuno- assay agreement with Beckman Coulter (Fullerton, California). The three-year contract is valued at $60 million. The renewal includes pricing agreements for Beckman Coulters entire line of immunoassay systems, test kits, supplies and services.
-
A report in the July 29 issue of Circulation, the journal of the American Heart Association (AHA; Dallas, Texas), says that prevention and education efforts must be pursued to curb the growing trend of hospitalizations for atrial fibrillation (AF) in the U.S.
-
Continuing its rapid pace of product approvals, Guidant (Indianapolis, Indiana) last month received the FDA's okay for the newest iteration of its cardiac resynchronization therapy defibrillator (CRT-D) the Contak Renewal 3 system.
-
-
An abdominal aortic aneurysm (AAA) is a balloon-like enlargement of the aorta, a vessel one-inch (2.5 cm) in diameter that is the largest blood vessel in the body, supplying blood to most organs. An enlarged aorta is considered to be an aneurysm when it expands to 150% of its normal size. On average, an AAA grows about 10% per year or 0.5 cm per year in larger aneurysms (over 6 cms).
-
Two powerhouse medical device companies reported significant developments in their cardiovascular stent programs in mid-July, with an emphasis on new, lighter materials. Guidant (Indianapolis, Indiana) gained U.S. approval for a significant new stent and Medtronic (Minneapolis, Minnesota) said it has begun a second trial for its Endeavor drug-eluting stent platform.
